Free Trial
NASDAQ:XERS

Xeris Biopharma (XERS) Stock Price, News & Analysis

Xeris Biopharma logo
$6.84 +0.24 (+3.64%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.82 -0.02 (-0.29%)
As of 08/8/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Xeris Biopharma Stock (NASDAQ:XERS)

Key Stats

Today's Range
$6.54
$6.93
50-Day Range
$4.35
$6.84
52-Week Range
$2.21
$7.09
Volume
11.44 million shs
Average Volume
2.36 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25
Consensus Rating
Moderate Buy

Company Overview

Xeris Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

XERS MarketRank™: 

Xeris Biopharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 382nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Xeris Biopharma has received no research coverage in the past 90 days.

  • Read more about Xeris Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xeris Biopharma is -32.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xeris Biopharma is -32.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    12.50% of the outstanding shares of Xeris Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently increased by 164.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xeris Biopharma does not currently pay a dividend.

  • Dividend Growth

    Xeris Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.50% of the outstanding shares of Xeris Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently increased by 164.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Xeris Biopharma has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    19 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 6.47% of the stock of Xeris Biopharma is held by insiders.

  • Percentage Held by Institutions

    42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xeris Biopharma's insider trading history.
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance
See More Headlines

XERS Stock Analysis - Frequently Asked Questions

Xeris Biopharma's stock was trading at $3.39 at the beginning of the year. Since then, XERS stock has increased by 101.8% and is now trading at $6.84.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its earnings results on Thursday, August, 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million.
Read the conference call transcript
.

Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Top institutional shareholders of Xeris Biopharma include Geode Capital Management LLC (2.33%), Connor Clark & Lunn Investment Management Ltd. (0.79%), Y Intercept Hong Kong Ltd (0.21%) and Diversified Trust Co (0.11%). Insiders that own company stock include Paul R Edick, Kevin Mcculloch, John Patrick Shannon Jr and Beth Hecht.
View institutional ownership trends
.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/07/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XERS
CIK
1867096
Fax
N/A
Employees
290
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.00
Potential Upside/Downside
-8.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$54.84 million
Net Margins
-13.01%
Pretax Margin
-21.41%
Return on Equity
N/A
Return on Assets
-8.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.72
Quick Ratio
1.17

Sales & Book Value

Annual Sales
$203.07 million
Price / Sales
5.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.20) per share
Price / Book
-34.20

Miscellaneous

Outstanding Shares
156,380,000
Free Float
146,267,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
0.65

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:XERS) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners